CO2017012397A2 - Fragmento de anticuerpo fab anti-ngf humano - Google Patents

Fragmento de anticuerpo fab anti-ngf humano

Info

Publication number
CO2017012397A2
CO2017012397A2 CONC2017/0012397A CO2017012397A CO2017012397A2 CO 2017012397 A2 CO2017012397 A2 CO 2017012397A2 CO 2017012397 A CO2017012397 A CO 2017012397A CO 2017012397 A2 CO2017012397 A2 CO 2017012397A2
Authority
CO
Colombia
Prior art keywords
human anti
fab antibody
fragment
ngf fab
seq
Prior art date
Application number
CONC2017/0012397A
Other languages
English (en)
Inventor
Hirotsugu Tanaka
Hirotada Fujita
Toshiaki Aoki
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of CO2017012397A2 publication Critical patent/CO2017012397A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

RESUMEN Se provee un fragmento de anticuerpo Fab anti-NGF humano superior, que conservara una actividad de neutralización elevada, que presentara menos efectos secundarios como resultado de una exposición sistémica y que pudiera ejercer un efecto farmacológico local. El objetivo se logra mediante un fragmento de anticuerpo Fab anti-NGF humano que comprende un fragmento de la cadena pesada que consiste en la secuencia de aminoácidos que se representa en SEQ ID Nº 5 y una cadena liviana que consiste en la secuencia de aminoácidos que se representa en SEQ ID Nº 8.
CONC2017/0012397A 2015-05-22 2017-11-30 Fragmento de anticuerpo fab anti-ngf humano CO2017012397A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015104806 2015-05-22
PCT/JP2016/065099 WO2016190263A1 (ja) 2015-05-22 2016-05-20 新規抗ヒトＮＧＦ抗体Ｆａｂフラグメント

Publications (1)

Publication Number Publication Date
CO2017012397A2 true CO2017012397A2 (es) 2018-02-28

Family

ID=57393503

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0012397A CO2017012397A2 (es) 2015-05-22 2017-11-30 Fragmento de anticuerpo fab anti-ngf humano

Country Status (22)

Country Link
US (1) US11260124B2 (es)
EP (1) EP3299461B1 (es)
JP (1) JP6700620B2 (es)
KR (1) KR102440054B1 (es)
CN (1) CN107614683B (es)
AR (1) AR104721A1 (es)
AU (1) AU2016268625B2 (es)
BR (1) BR112017025029A2 (es)
CA (1) CA2986210C (es)
CO (1) CO2017012397A2 (es)
HK (1) HK1246349A1 (es)
IL (1) IL255832B (es)
MA (1) MA42138A (es)
MX (1) MX2017014911A (es)
MY (1) MY184164A (es)
PH (1) PH12017502126A1 (es)
RU (1) RU2729825C2 (es)
SG (1) SG11201709589XA (es)
TW (1) TWI706959B (es)
UA (1) UA123209C2 (es)
WO (1) WO2016190263A1 (es)
ZA (1) ZA201708169B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016164477A1 (en) * 2015-04-06 2016-10-13 Meso Scale Technologies, Llc. High throughput system for performing assays using electrochemiluminescence including a consumable shaking apparatus
NL2017890B1 (nl) * 2016-11-29 2018-06-11 Josh Ip Iii B V Medische transportinrichting, hulpaandrijving, en werkwijze voor het transporteren van een dergelijke transportinrichting
EP3795176A4 (en) 2018-05-15 2022-01-12 Astellas Pharma Inc. PHARMACEUTICAL COMPOSITION FOR SUPPRESSION OF ATRIAL FIBRILLATION WITH ANTI-HUMAN NGF ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AS AN ACTIVE SUBSTANCE

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5527358A (en) 1994-01-21 1996-06-18 Medtronic, Inc. Temporary medical electrical lead
CA2500901A1 (en) 2002-10-04 2004-04-22 Rinat Neuroscience Corp. Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
NZ540730A (en) 2002-12-24 2010-09-30 Rinat Neuroscience Corp Anti-NGF antibodies and methods using same
NZ599196A (en) 2003-07-15 2014-01-31 Amgen Inc Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
KR101504729B1 (ko) * 2004-04-07 2015-03-19 리나트 뉴로사이언스 코프. 신경성장인자 길항제의 투여에 의한 골암 통증 치료용 약학적 조성물
KR101298383B1 (ko) * 2005-01-24 2013-08-20 엘란 파마 인터내셔널 리미티드 Ｎｇｆ에 대한 특이적 결합 멤버
US9532943B2 (en) 2010-12-20 2017-01-03 Cormatrix Cardiovascular, Inc. Drug eluting patch for the treatment of localized tissue disease or defect
JP2007244601A (ja) 2006-03-15 2007-09-27 Kanazawa Univ 心筋用パッド
PT2187964E (pt) 2007-08-10 2015-01-14 Regeneron Pharma Anticorpos humanos de elevada afinidade para o factor de crescimento neural humano
WO2010106812A1 (en) 2009-03-19 2010-09-23 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical formulation containing improved antibody molecules
PT2448970E (pt) 2009-05-04 2014-10-20 Abbvie Res B V Anticorpos contra factor de crescimento nervoso (ngf) com estabilidade in vivo melhorada
SG191737A1 (en) 2010-12-20 2013-08-30 Cormatrix Cardiovascular Inc A drug eluting patch for the treatment of localized tissue disease or defect
ES2704007T3 (es) * 2011-05-06 2019-03-13 Nexvet Australia Pty Ltd Anticuerpos anti-factor de crecimiento nervioso y procedimientos de preparación y uso de los mismos
GB201114858D0 (en) * 2011-08-29 2011-10-12 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of using the same
KR101783929B1 (ko) * 2011-05-06 2017-10-11 넥스베트 오스트레일리아 피티와이 리미티드 항신경성 성장 인자 항체 및 그의 제조방법과 이용방법
US8986952B2 (en) * 2011-08-11 2015-03-24 Astellas Pharma Inc. Anti-human NGF antibody
EA201492163A1 (ru) 2012-06-08 2015-08-31 Гленмарк Фармасьютикалс С.А. ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К TrkA, СОДЕРЖАЩИЕ АМИНОКИСЛОТНЫЕ ЗАМЕНЫ
JP6135161B2 (ja) * 2013-02-08 2017-05-31 アステラス製薬株式会社 新規抗ヒトｎｇｆ抗体
US9127055B2 (en) * 2013-02-08 2015-09-08 Astellas Pharma Inc. Method of treating pain with anti-human NGF antibody
AU2015362775B2 (en) 2014-12-17 2019-07-04 Dow Global Technologies Llc Viscoelastic polyurethane foam with aqueous polymer dispersion

Also Published As

Publication number Publication date
MX2017014911A (es) 2018-03-23
HK1246349A1 (zh) 2018-09-07
ZA201708169B (en) 2019-06-26
IL255832B (en) 2021-07-29
SG11201709589XA (en) 2017-12-28
EP3299461A4 (en) 2018-12-19
CA2986210A1 (en) 2016-12-01
EP3299461A1 (en) 2018-03-28
EP3299461B1 (en) 2023-03-29
CA2986210C (en) 2022-04-26
KR102440054B1 (ko) 2022-09-06
AR104721A1 (es) 2017-08-09
BR112017025029A2 (pt) 2018-08-07
MY184164A (en) 2021-03-24
TW201713691A (zh) 2017-04-16
UA123209C2 (uk) 2021-03-03
AU2016268625B2 (en) 2022-01-27
IL255832A (en) 2018-01-31
US20180147281A1 (en) 2018-05-31
CN107614683B (zh) 2020-12-22
US11260124B2 (en) 2022-03-01
KR20180006391A (ko) 2018-01-17
AU2016268625A1 (en) 2017-12-07
JP6700620B2 (ja) 2020-05-27
CN107614683A (zh) 2018-01-19
PH12017502126A1 (en) 2018-05-07
JPWO2016190263A1 (ja) 2018-04-12
RU2017145071A (ru) 2019-06-24
MA42138A (fr) 2018-03-28
RU2729825C2 (ru) 2020-08-12
TWI706959B (zh) 2020-10-11
RU2017145071A3 (es) 2019-10-17
WO2016190263A1 (ja) 2016-12-01

Similar Documents

Publication Publication Date Title
CY1123065T1 (el) Ανασυνδυασμενα προβιοτικα βακτηριδια
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
PE20161390A1 (es) Anticuerpos multiespecificos
CL2017002728A1 (es) Método para el tratamiento de cáncer
EA201890945A1 (ru) Биологические препараты и их применение в отношении растений
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
PE20170665A1 (es) Anticuerpos anti-tau humanizados
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
CR20170197A (es) Proteinas de variantes de secuencias de aminoacidos de cry1da1 activas para lepidópteros
CL2018001565A1 (es) Inmunoglobulinas conjugadas con lisina c-terminal
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
EA201890442A1 (ru) Получение фоторецепторов для лечения заболеваний сетчатки
CL2019003670A1 (es) Composición que comprende manosa oligosacárido y proceso para realizarla y uso de esta.
CO2022002622A2 (es) Anticuerpos anti-cd73 y composiciones
CO2017012397A2 (es) Fragmento de anticuerpo fab anti-ngf humano
ECSP17013904A (es) Angiopoietin-like 4 antibodies and methods of use
EA201892203A1 (ru) Оксабороловые сложные эфиры, их применение
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
AR101671A1 (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso
CO2019003865A2 (es) Proteína terapéutica
UY36173A (es) Metodo de tratamiento de enfermedades relacionadas con el factor inducible por hipoxia
SE1651620A1 (sv) A field emission light source adapted to emit UV light
EA201791716A1 (ru) Фармацевтический состав